Copyright
©The Author(s) 2019.
World J Gastrointest Pathophysiol. Sep 10, 2019; 10(2): 17-28
Published online Sep 10, 2019. doi: 10.4291/wjgp.v10.i2.17
Published online Sep 10, 2019. doi: 10.4291/wjgp.v10.i2.17
Table 2 Definition of diarrhea and colitis based on Common Terminology Criteria for Adverse Events v5.0[32]
CTCAE Term | Definition | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | CTCAE v5.0 Change |
Diarrhea | A disorder characterized by an increase in frequency and/or loose or watery bowel movements | Increase of < 4 stools per day over baseline; mild increase in ostomy output compared to baseline | Increase of 4-6 stools per day over baseline; moderate increase in ostomy output compared to baseline; limiting instrumental ADL | Increase of ≥ 7 stools per day over baseline; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self-care ADL | Life-threatening consequences; urgent intervention indicated | Death | Clarification: Grade 2, 3, Definition |
Colitis | A disorder characterized by inflammation of the colon | Asymptomatic; clinical or diagnostic observations only; intervention not indicated | Abdominal pain; mucus or blood in stool | Severe abdominal pain; peritoneal signs | Life-threatening consequences; urgent intervention indicated | Death | Addition: Navigational note; Clarification: Grade 3 |
- Citation: Nishida T, Iijima H, Adachi S. Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World J Gastrointest Pathophysiol 2019; 10(2): 17-28
- URL: https://www.wjgnet.com/2150-5330/full/v10/i2/17.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v10.i2.17